Helping Patients Access Anktiva: A Provider's Playbook

Your patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) are facing a uniquely challenging treatment access landscape. Anktiva (nogapendekin alfa inbakicept-pmln), the first IL-15 superagonist approved for this indication, offers a meaningful chance at bladder preservation — but navigating supply chain realities, BCG shortages, and insurance requirements demands proactive effort from the clinical team.

This guide provides actionable strategies for urologists, oncologists, and practice administrators to help patients find and access Anktiva treatment in 2026.

Understanding the Current Access Barriers

Before implementing solutions, it's important to understand the specific barriers your patients face:

• BCG supply constraints: Merck remains the sole U.S. BCG supplier, and the shortage has worsened. Without BCG, Anktiva cannot be administered per the approved indication.
• Specialty distribution model: Anktiva is only available through specialty distributors (Cencora), not retail pharmacies. Practices must have an established ordering relationship.
• Prior authorization requirements: All major payers require prior authorization with documented BCG-unresponsive status.
• Limited provider familiarity: Newer practices may not yet have the infrastructure or experience to order and administer Anktiva.
• Cost: At $35,800 WAC per dose, out-of-pocket costs without insurance coverage or financial assistance are prohibitive.

Strategy 1: Establish Your Supply Chain

If your practice does not currently carry Anktiva, the onboarding process is straightforward:

1. Contact Cencora (formerly AmerisourceBergen) at 1-888-711-5469 to set up a specialty distribution account
2. Register with the ImmunityBio CARE program at 1-877-ANKTIVA (1-877-265-8482) for provider support
3. Verify billing infrastructure: Ensure your practice can bill using J-code J9028 and the appropriate CPT codes for intravesical instillation
4. Secure BCG supply: Coordinate with your BCG distributor to ensure adequate supply for combination therapy. Consider enrolling in the rBCG expanded access program as a backup supply source.

Practices that proactively establish their supply chain will be better positioned to serve patients as Anktiva adoption continues to grow.

Strategy 2: Optimize the Prior Authorization Process

Prior authorization is the most common source of treatment delays. Streamline your process with these steps:

Documentation Checklist

Prepare the following before submitting prior authorization requests:

• Pathology reports confirming NMIBC with CIS (with or without papillary tumors)
• BCG treatment history documenting adequate prior BCG therapy (minimum of one full induction course)
• Evidence of BCG-unresponsive disease: Persistent or recurrent CIS within 12 months of adequate BCG, or recurrent high-grade Ta/T1 within 6 months
• Clinical rationale for Anktiva + BCG combination therapy, including patient's candidacy for cystectomy
• Letter of medical necessity citing FDA-approved indication and relevant clinical trial data (QUILT-3.032)

Leverage the CARE Program

The ImmunityBio CARE program provides dedicated reimbursement support:

• Benefits investigation for individual patients
• Prior authorization submission assistance and tracking
• Payer-specific appeal templates and strategies for denials
• Coding and billing consultation

Making the CARE program your first call for every Anktiva patient can significantly reduce administrative burden on your practice staff.

Strategy 3: Develop a BCG Allocation Protocol

With BCG in short supply, your practice should have a formal protocol for allocating limited BCG stock. Recommended considerations:

• Tier 1 — Highest priority: Patients currently on Anktiva + BCG induction or maintenance (interrupting treatment may compromise outcomes)
• Tier 2: New patients eligible for Anktiva + BCG who have exhausted other options and are not candidates for cystectomy
• Tier 3: BCG-naïve high-risk NMIBC patients starting initial induction

For patients who cannot receive BCG, consider BCG-independent alternatives (Pembrolizumab, Adstiladrin, Gemcitabine/Docetaxel) while continuing to work on BCG access.

Strategy 4: Build a Referral Network

Not every practice can or should carry Anktiva. If you're a community urologist referring patients for Anktiva treatment:

• Identify 2-3 regional centers that carry Anktiva and have BCG access
• Establish warm referral pathways with urologic oncologists at these centers
• Share patient records proactively — include BCG treatment history, pathology, and imaging to expedite the receiving center's prior authorization process
• Coordinate ongoing care: Many patients can receive Anktiva treatment at the referral center while continuing routine surveillance with you

Direct patients and colleagues to MedFinder for Providers to search for treatment centers with current Anktiva availability.

Strategy 5: Utilize Financial Assistance Programs

Cost should not prevent eligible patients from accessing Anktiva. Ensure your patients know about available programs:

• Copay assistance: Commercially insured patients may pay as little as $100 per dose (maximum benefit $25,000). Not available for Medicare, Medicaid, or other government program enrollees.
• Patient assistance program: For uninsured or underinsured patients who meet eligibility criteria
• Foundation assistance: Cancer-specific foundations may offer additional grants for treatment-related expenses

Your practice's financial counselor or the CARE program can help determine which programs each patient qualifies for. See our provider's guide to helping patients save money on Anktiva for more detail.

Strategy 6: Educate Your Clinical Team

Ensure all members of your clinical team — nurses, medical assistants, practice coordinators — are familiar with:

• The Anktiva administration protocol: Intravesical instillation with BCG, 2-hour dwell time, proper catheterization technique
• Storage requirements: Refrigerate at 2°C–8°C in original carton, protect from light, do not freeze or shake
• Patient counseling points: Expected side effects (dysuria, hematuria, urgency), the importance of completing the full treatment course, contraception requirements for females of reproductive potential
• When to escalate: Signs of serious adverse events including significant hematuria or cardiac symptoms

Strategy 7: Stay Informed on Pipeline Developments

The Anktiva treatment landscape is evolving rapidly. Key developments to track:

• rBCG approval timeline: ImmunityBio's recombinant BCG could fundamentally change the supply equation
• Papillary-only indication: Supplemental BLA submitted for BCG-unresponsive papillary NMIBC without CIS
• European authorization: EMA conditional marketing authorization recommendation could expand global supply
• NSCLC expansion: Anktiva is being studied in non-small cell lung cancer, which could drive manufacturing scale

Patient Communication Template

When discussing Anktiva access challenges with patients, consider addressing:

1. Set realistic timelines: "Getting Anktiva set up may take a few weeks for insurance approval and supply coordination."
2. Acknowledge the BCG challenge: "We need both Anktiva and BCG for your treatment. BCG is in limited supply, and we're working to secure it."
3. Outline the plan: "While we work on Anktiva access, we'll discuss alternative options so you're not without treatment."
4. Provide resources: Direct patients to MedFinder.com and the CARE program

Related Articles

• Anktiva Shortage: What Providers Need to Know in 2026
• How to Help Patients Save Money on Anktiva
• Anktiva Drug Interactions: What to Avoid
• How Does Anktiva Work? Mechanism of Action Explained